Skip to content
value.today

Cambrian BioPharma Inc

🇺🇸 New York, New York, USABiotechnologyFounded 2019
Total raised
$148 M
4 rounds on record
Latest round
$23 M
Jun 2023
First round on record
Oct 2019
Today
Private
No later event on record

Funding rounds

4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Cambrian BioPharma Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2026$124 MIssued in a merger or acquisition$50 to $250 million

Cambrian BioPharma Inc: Private sale, Jun 2026

Investors in this round

80 investors had bought by the notice of Jul 15, 2026: 80 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$124 M of $130 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Peyer · Executive Officer, Director
  • Juliette Han · Executive Officer, Director
  • Mark Nuttall · Executive Officer
  • Ruth Thieroff-Ekerdt · Executive Officer
  • William DeVaul · Executive Officer
  • Brenton L. Saunders · Director
  • Christian Angermeyer · Director
  • Lorin L. Van Nuland · Director
  • Martin L. Gunhaga · Director
  • Maryanna Saenko · Director
  • Paul L. Farr · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “46,210,122 shares were offered in a business combination whereby the Issuer issued 7,988,207 Common and 38,221,915 Preferred shares to shareholders of a certain company in exchange for their shares, increasing the Issuer's ownership to 100%.”

Signed by William DeVaul, Chief Legal Officer. Source: SEC Form D, newest notice filed Jul 15, 2026. Read the notice at the SEC.

equitySEC
Jun 2023$23 MNo. 4$10 to $50 million

Cambrian BioPharma Inc: Raise no. 4, Jun 2023

Investors in this round

30 investors had bought by the notice of Jan 13, 2025: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$23 M of $38 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, other: Simple Agreement for Future Equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James G. Peyer · Executive Officer, Director
  • Brenton G. Saunders · Director
  • Christian G. Angermayer · Director
  • Maryanna G. Saenko · Director
  • Paul G. Farr · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James G. Peyer, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 13, 2025. Read the notice at the SEC.

optionsSEC
Oct 2021$92 MNo. 3$50 to $250 million

Cambrian BioPharma Inc: Raise no. 3, Oct 2021

Investors in this round

56 investors had bought by the notice of Dec 2, 2021: 56 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$92 M of $101 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James G. Peyer · Executive Officer, Director, Promoter
  • Christian G. Angermayer · Director
  • Maryanna G. Saenko · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James G. Peyer, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 2, 2021. Read the notice at the SEC.

equity, optionsSEC
Oct 2020$28 MNo. 2$10 to $50 million

Cambrian BioPharma Inc: Raise no. 2, Oct 2020

Investors in this round

30 investors had bought by the notice of May 6, 2021: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$28 M of $28 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James G. Peyer · Executive Officer, Director, Promoter
  • Christian G. Angermeyer · Director
  • Maryanna G. Saenko · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Total Offering amount and Total Amount Sold includes a $4,000,000 convertible promissory note.”

Signed by James G. Peyer, Chief Executive Officer. Source: SEC Form D, newest notice filed May 6, 2021. Read the notice at the SEC.

equity, debt, optionsSEC
Oct 2019$5 MNo. 1$2 to $10 million

Cambrian BioPharma Inc: Raise no. 1, Oct 2019

Investors in this round

5 investors had bought by the notice of Jan 27, 2020: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James G. Peyer · Executive Officer, Director, Promoter
  • Christian G. Angermeyer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James G. Peyer, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 27, 2020. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cambrian BioPharma Inc chose not to state its revenue in its newest notice of a funding round (Jul 2026).

    SEC Form D · Jul 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2026

That is all the official record says: Cambrian BioPharma Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Cambrian BioPharma Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 56 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cambrian BioPharma Inc
NameRoleNamed in
James PeyerExecutive officerJul 2026
Juliette HanExecutive officerJul 2026
Mark NuttallExecutive officerJul 2026
Ruth Thieroff-EkerdtExecutive officerJul 2026
William DeVaulExecutive officerJul 2026
James G. PeyerExecutive officerJan 2025
Brenton L. SaundersDirectorJul 2026
Christian AngermeyerDirectorJul 2026
James PeyerDirectorJul 2026
Juliette HanDirectorJul 2026
Lorin L. Van NulandDirectorJul 2026
Martin L. GunhagaDirectorJul 2026
Maryanna SaenkoDirectorJul 2026
Paul L. FarrDirectorJul 2026
Brenton G. SaundersDirectorJan 2025
Christian G. AngermayerDirectorJan 2025
James G. PeyerDirectorJan 2025
Maryanna G. SaenkoDirectorJan 2025
Paul G. FarrDirectorJan 2025
Christian G. AngermeyerDirectorMay 2021
James G. PeyerPromoterDec 2021